Vera's Trutakna Posts Strong Phase 3 Results in IgAN — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Trutakna stabilized kidney function and reduced the risk of kidney-related death and other complications in IgA nephropathy patients, according to final two-year results from Vera's Phase 3 trial reported Tuesday
- Vera Therapeutics said it will seek full FDA approval of Trutakna during the fourth quarter now that the confirmatory Phase 3 data are in hand
- The FDA granted Trutakna accelerated approval in July, clearing it as a treatment for IgA nephropathy, a chronic autoimmune disease driven by immune-antibody buildup in the kidneys
- IgA nephropathy causes progressive loss of kidney function and can lead to organ failure requiring dialysis, making disease-stabilizing treatment a high-stakes need for the patient population
- The Phase 3 readout shifts Trutakna from an accelerated-approval foothold — granted on earlier data — to a full-approval submission backed by two years of follow-up, a step that typically enables broader reimbursement and label expansion
Why it matters: Accelerated approval let Vera commercialize Trutakna early; the two-year Phase 3 readout now underwrites a full-approval filing in Q4, the regulatory milestone that typically unlocks broader reimbursement and physician adoption for an IgAN patient population facing progressive kidney failure and dialysis.
Ask SkimNews
